| |
United Healthcare Criteria for Harvoni
|
| |
| |
United Healthcare Criteria for Harvoni - Click Here .....8, 12 & 24 Weeks
Download the PDF here
Effective Date 10/15/2014
Background:
Harvoni™ (ledipasvir/sofosbuvir) is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.1
|
|
| |
| |
|
|
|
